Metacen Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
2ndary - Private
- Investors
-
3
Metacen Therapeutics General Information
Description
Developer of metabolic health therapies designed for the management of metabolic disease pathways. The company's platform utilizes AGE-reduction technologies, probiotic-based research, metabolic disease studies, and therapeutic development activities, enabling healthcare and life sciences organizations to support disease prevention, metabolic health management, and treatment research.
Contact Information
Website
www.metacen.comCorporate Office
- 91, Changryong-daero 256beon-gil, Yeongtong-gu
- 1007, 10th Floor, 16229
- Suwon, Gyeonggi 443-270
- South Korea
Corporate Office
- 91, Changryong-daero 256beon-gil, Yeongtong-gu
- 1007, 10th Floor, 16229
- Suwon, Gyeonggi 443-270
- South Korea
Metacen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 3. Later Stage VC (Series B) | 16-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 01-Jan-2017 | $2.69M | $3.54M | Completed | Startup | |
| 1. Seed Round | 01-Jan-2016 | $847K | $847K | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Metacen Therapeutics Patents
Metacen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026054258-A1 | Composition for treating fatty liver comprising lactococcus lactis strain, amino acids, and vitamin | Pending | 03-Sep-2024 | ||
| WO-2025170200-A1 | Novel composition comprising wheat germ extract | Pending | 06-Feb-2024 | ||
| WO-2025170198-A1 | Zinc transporter activator composition | Pending | 06-Feb-2024 | ||
| WO-2023234620-A1 | Novel strain having resistance to methylglyoxal and use thereof | Inactive | 03-Jun-2022 | ||
| JP-2024536636-A | A novel strain having antagonistic activity against proteus mirabilis and having excellent effects on neurodegenerative diseases, and its use | Active | 19-Oct-2021 | A61K35/744 |
Metacen Therapeutics Signals
Metacen Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DA Value Investment | Growth/Expansion | Minority | ||
| Gravity Ventures (Korea) | Corporate Venture Capital | Minority | ||
| Vision Creator | Venture Capital | Minority |
Metacen Therapeutics FAQs
-
When was Metacen Therapeutics founded?
Metacen Therapeutics was founded in 2015.
-
Where is Metacen Therapeutics headquartered?
Metacen Therapeutics is headquartered in Suwon, South Korea.
-
What is the size of Metacen Therapeutics?
Metacen Therapeutics has 24 total employees.
-
What industry is Metacen Therapeutics in?
Metacen Therapeutics’s primary industry is Drug Discovery.
-
Is Metacen Therapeutics a private or public company?
Metacen Therapeutics is a Private company.
-
What is Metacen Therapeutics’s current revenue?
The current revenue for Metacen Therapeutics is .
-
How much funding has Metacen Therapeutics raised over time?
Metacen Therapeutics has raised $9M.
-
Who are Metacen Therapeutics’s investors?
DA Value Investment, Gravity Ventures (Korea), and Vision Creator have invested in Metacen Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process